- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05152992
Spatiotemporal Dynamics of the Human Emotion Network
May 10, 2023 updated by: University of California, San Francisco
The overall goal of this study is to elucidate how emotion network dynamics relate to the behavioral, autonomic, and experiential changes that accompany emotions and to investigate how emotion network dysfunction relates to affective symptoms.
Affective symptoms are a common feature of neuropsychiatric disorders that reflect dysfunction in a distributed brain network that supports emotion.
How aberrant functioning in a single emotion network underlies a wide range of affective symptoms, such as depression and anxiety, is not well understood.
Anchored by the anterior cingulate cortex and ventral anterior insula, the emotion network responds to numerous affective stimuli.
The recording of neural activity directly from the cortical surface from individuals is a promising approach since intracranial electroencephalography (iEEG) can provide direct estimates of neuronal populations to map the spatiotemporal dynamics of the emotion network at a millisecond level resolution.
This study will exam how activity within emotion network hubs changes during emotions and how emotion network properties make some individuals more vulnerable to affective symptoms than others.
A multidisciplinary approach is critical for understanding the dynamic brain network to advance neuroanatomical models of emotions and for guiding the development of novel treatments for affective symptoms.
Study Overview
Status
Enrolling by invitation
Conditions
Intervention / Treatment
Detailed Description
Intracranial EEG (iEEG) recordings make it possible to obtain direct measures of emotion network dynamics not possible with other methods.
This study proposes to conduct a multimodal assessment of emotions in patients with epilepsy who are undergoing surgery for seizure localization.
Electrodes will be placed in sites based on the clinical needs of each patient and will include sites within and outside of the emotion network.
The research study team will examine measures of behavior, autonomic nervous system (ANS) activity, and subjective experience to continuous iEEG recordings to determine how emotion network dynamics relate to emotions and affective symptoms.
Affective symptoms are common in epilepsy, with nearly one third of patients meeting diagnostic criteria for a severe anxiety or depressive disorder during their lifetimes.
This clinical population offers a unique opportunity to obtain direct recordings of emotion network activity with concurrent measures of emotion physiology and behavior.
The aims of this study seeks to determine how emotion network activity relates to naturalistic affective behaviors (Aim 1), whether we can uncover the unique neural signatures of discrete emotions and examine their relation to task-based measures of emotional reactivity (Aim 2), and whether electrical stimulation of emotion network changes network activity and alters emotions, mood, and anxiety (Aim 3).
Together, these aims will help to uncover the neural mechanisms that produce, sense, and regulate emotions.
These results should heavily impact the current understanding of the neurobiological systems that underlie affective symptoms and, therefore, will have significant implications for identifying biomarkers of system dysfunction to guide development of new treatments.
Study Type
Interventional
Enrollment (Anticipated)
100
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
San Francisco, California, United States, 94143
- University of California, San Francisco
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 50 years (Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Participants with epilepsy at UCSF undergoing surgical electrode implantation for seizure localization and
- Participants with electrodes implanted in at least two regions of interest who are willing and able to cooperate with study tasks.
Exclusion Criteria:
- Participants who lack capacity or decline to provide informed consent,
- Participants who have significant cerebral lesions or
- Participants with cognitive deficits that preclude reliable completion of study tasks.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Video and stimulation-based induction of emotion
Participants viewed visual stimuli while undergoing stimulation of brain regions involved in emotion during their inpatient hospitalization at the University of California, San Francisco (UCSF).
|
View emotionally evocative videos and undergo stimulation of brain regions involved in emotion.
In a 20-minute block (5 total blocks), eighteen 30-second movie clips will be used to elicit different categories of emotions (sadness, fear, disgust, awe, affection, and amusement).
Additionally, each hub of the emotion network will be stimulated to identify areas that generate similar emotional states as those elicited by the videos.
Each stimulation trial consists of 3 minutes of 1-3 mA, 50 Hz, 100 us pulse-width stimulation.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Change from Baseline in Heart Rate
Time Frame: During inpatient hospitalization, approximately 4-14 days
|
The mean change from baseline in heart rate is calculated as the average change in heart rate across trials of each emotion video type and stimulated network hub (units: beats/minute).
The change from baseline in heart rate on each trial is calculated as: change = (mean heart rate during a trial) - (mean heart rate prior to the trial).
Note: this is one of three components of the autonomic nervous system activity outcome measure.
|
During inpatient hospitalization, approximately 4-14 days
|
Mean Change from Baseline in Respiratory Rate
Time Frame: During inpatient hospitalization, approximately 4-14 days
|
The mean change from baseline in respiratory rate is calculated as the average change in respiratory rate across trials of each emotion video type and stimulated network hub (units: breaths/minute).
The change from baseline in respiratory rate on each trial is calculated as: change = (mean respiratory rate during a trial) - (mean respiratory rate prior to the trial).
Note: this is one of three components of the autonomic nervous system activity outcome measure.
|
During inpatient hospitalization, approximately 4-14 days
|
Mean change from Baseline in Electrodermal Activity
Time Frame: During inpatient hospitalization, approximately 4-14 days
|
The mean change from baseline in Electrodermal Activity (EDA) is calculated as the average change in EDA across trials of each emotion video type and stimulated network hub (units: microsiemens).The change from baseline in electrodermal activity on each trial is calculated as: change = (mean electrodermal activity during a trial) - (mean electrodermal activity prior to the trial).
Note: this is one of three components of the autonomic nervous system activity outcome measure.
|
During inpatient hospitalization, approximately 4-14 days
|
Mean Facial Expression Activity
Time Frame: During inpatient hospitalization, approximately 4-14 days
|
Mean facial expression activity (units: activation intensity) is quantified for each video emotion type and stimulated network hub.
This is measured using the validated Emotional Facial Action Coding System (FACS) to provide a continuous rating of activity in 28 facial muscles using an intensity scale from 1 (trace) to 5 (maximum).
The activity scores of all muscles and across the duration of a trial will be summed to quantify the total facial expression activity of that trial.
Trials will be averaged for each video emotion type and stimulated network hub to obtain mean facial expression activity.
|
During inpatient hospitalization, approximately 4-14 days
|
Mean Change from Baseline in Neural Activity within the Emotion Network
Time Frame: During inpatient hospitalization, approximately 4-14 days
|
The mean change from baseline in neural activity is calculated as the average change in neural activity across trials of each emotion video type and stimulated network hub (units: z-scored neural activity relative to the pretrial baseline).
The change from baseline in neural activity on each trial is calculated as: change = (z-scored mean neural activity across the network during a trial) - (z-scored mean neural activity across the network prior to the trial).
|
During inpatient hospitalization, approximately 4-14 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Subjective Experience
Time Frame: During inpatient hospitalization, approximately 4-14 days
|
The mean subjective experience is calculated as the average subjective experience rating across trials of each emotion video type and stimulated network hub (units: arbitrary units [a.u.] on a scale from 0-10; 0 = no emotion felt, 10 = maximum emotion felt ).
Trials will be averaged for each video emotion type and stimulated network hub to obtain mean subjective experience.
|
During inpatient hospitalization, approximately 4-14 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Edward F Chang, MD, University of California, San Francisco
- Principal Investigator: Virginia Sturm, PhD, University of California, San Francisco
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 19, 2019
Primary Completion (Anticipated)
June 30, 2026
Study Completion (Anticipated)
June 30, 2026
Study Registration Dates
First Submitted
November 29, 2021
First Submitted That Met QC Criteria
November 29, 2021
First Posted (Actual)
December 10, 2021
Study Record Updates
Last Update Posted (Actual)
May 12, 2023
Last Update Submitted That Met QC Criteria
May 10, 2023
Last Verified
May 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- R01MH122431 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
ProgenaBiomeRecruitingDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Vituity PsychiatryRecruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
University of California, San FranciscoRecruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
University GhentUniversiteit Antwerpen; Janssen-Cilag Ltd.RecruitingDepression Moderate | Depression Severe | Depression MildBelgium
-
Baylor College of MedicineUniversity of TexasRecruitingDepression | Depression Moderate | Depression Severe | Suicide and Self-harm | Depression in Adolescence | Depression MildUnited States
-
University of Cape TownNational Institute of Mental Health (NIMH)CompletedPostpartum Depression | Clinical Depression | Moderate DepressionSouth Africa
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; National Institute of Mental...CompletedMajor Depressive Disorder | Treatment Resistant Depression | Treatment-Refractory Depression | Late Life Depression | Geriatric DepressionUnited States, Canada
-
Northern Illinois UniversityUniversity Autonoma de Santo DomingoTerminatedDepression Moderate | Depression MildUnited States, Dominican Republic
-
Lawson Health Research InstituteTerminated
Clinical Trials on Viewing visual stimuli and electrical stimulation of the brain
-
University of ZurichUnknown
-
Amit SethiRecruiting
-
Fondation Ophtalmologique Adolphe de RothschildTerminated
-
Federal University of Health Science of Porto AlegreCompleted
-
KU LeuvenCompletedObsessive-Compulsive DisorderBelgium
-
DuBois Vision ClinicWithdrawnDry Macular Degeneration
-
University of OstravaTechnical University of Ostrava; DAP ITRecruiting
-
Hospital do CoracaoCompleted
-
Hospital do CoracaoCompleted
-
Centre Hospitalier Universitaire de NiceRecruiting